Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 14, 2020

SELL
$2.97 - $5.22 $573,578 - $1.01 Million
-193,124 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$2.67 - $4.97 $1.75 Million - $3.26 Million
-654,945 Reduced 77.23%
193,124 $608,000
Q4 2019

Feb 14, 2020

SELL
$2.93 - $4.5 $756,974 - $1.16 Million
-258,353 Reduced 23.35%
848,069 $3.42 Million
Q1 2019

May 15, 2019

SELL
$5.36 - $7.24 $29,555 - $39,921
-5,514 Reduced 0.5%
1,106,422 $5.93 Million
Q4 2018

Feb 14, 2019

BUY
$4.8 - $11.6 $574,992 - $1.39 Million
119,790 Added 12.07%
1,111,936 $5.7 Million
Q3 2018

Nov 14, 2018

BUY
$9.05 - $10.95 $1.95 Million - $2.36 Million
215,837 Added 27.8%
992,146 $9.62 Million
Q2 2018

Aug 14, 2018

BUY
$10.2 - $13.9 $6.97 Million - $9.49 Million
682,959 Added 731.61%
776,309 $7.92 Million
Q1 2018

May 15, 2018

BUY
$12.65 - $18.85 $1.18 Million - $1.76 Million
93,350 New
93,350 $1.21 Million

Others Institutions Holding PRTK

About Paratek Pharmaceuticals, Inc.


  • Ticker PRTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,862,500
  • Description
  • Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...
More about PRTK
Track This Portfolio

Track Arbiter Partners Capital Management LLC Portfolio

Follow Arbiter Partners Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arbiter Partners Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Arbiter Partners Capital Management LLC with notifications on news.